Inflammatory pain, such as arthritis pain, is a growing health problem 1 Resolution of acute inflammation, once thought to be a passive pro cess, is now shown to involve active biochemical programs that enable inflamed tissues to return to homeostasis 2 . The actions of proresolu tion mediators differ from currently used antiinflammatory thera peutics. For example, inhibitors of COX and lipoxygenases disrupt resolution, because these enzymes are also required for the biosynthe sis of proresolution mediators [4] [5] [6] . Resolvins, such as RvD1 and RvE1, are biosynthesized from the omega3 fatty acids docosahexaenoic acid and eicosapentaenoic acid, respectively, and show remarkable potency in resolving inflammationrelated diseases such as periodon tal diseases, asthma and retinopathy 2, 3, 7 . The peripheral and central mechanisms of inflammatory pain are not fully understood [8] [9] [10] [11] . Here we examined whether peripheral and central resolvins can attenuate inflammatory pain, and we further investigated how resolvins regulate the synaptic plasticity in spinal cord dorsal horn neurons that has been strongly implicated in the generation of persistent pain 10, 11 .
First, we examined the actions of RvE1 in an acute inflammatory pain model induced by intraplantar injection of formalin in CD1 mice. Formalin induces two phases of spontaneous pain behavior. The second phase is thought to be mediated via central mechanisms within the spinal cord 12, 13 . We delivered synthetic resolvins to the mouse spinal cord via the intrathecal route by lumbar puncture 14, 15 . Preemptive injection of RvE1 at very low doses, only 0.3 and 1.0 ng (that is, 1 and 3 pmol), decreased secondphase (10-45 min) but not firstphase pain behavior (0-10 min), suggesting a central mechanism of action for RvE1 (Fig. 1a,b) . Notably, the effective dose range of RvE1 was much lower than that of either morphine or the COX2 inhibitor NS398 (Fig. 1c) .
Next, we investigated whether RvE1's antinociceptive action is mediated by specific receptors. ChemR23, which is associated with the G protein subunit G α i, has been identified as RvE1's receptor 16, 17 . Spinal injection of the G α i inhibitor pertussis toxin abrogated the action of RvE1 (Fig. 1d) , suggesting a possible involvement of G protein-coupled receptors (GPCRs). Opioid receptors did not mediate the antinociceptive action of RvE1, as the opioid receptor antagonist naloxone reversed the effect of morphine but not that of RvE1 (Fig. 1d) . Chemerin, a peptide agonist for ChemR23 (ref. 18) , also attenuated formalininduced secondphase pain in a dosedependent manner (Fig. 1e) . Notably, knockdown of ChemR23 with a specific siRNA abolished the antinociceptive actions of RvE1 (Supplementary Fig. 1 ). In situ hybridization revealed expression of ChemR23 mRNA in the dorsal root ganglion (DRG) and spinal cord (Fig. 1f) . Double staining further showed expression of ChemR23 pro tein in DRG neurons that express TRPV1 ( Fig. 1g and Supplementary  Fig. 2 ) and in spinal cord cells that express the neuronal marker NeuN (Supplementary Fig. 3a-c) . We also found ChemR23 in axons of DRG neurons (Fig. 1g) and primary afferent terminals in the spinal cord (Supplementary Fig. 3d ). Therefore, RvE1 might attenu ate inflammatory pain via ChemR23 expressed in DRG and spinal cord neurons.
Intraplantar injection of CFA elicits persistent inflammatory pain for weeks 19 . Intrathecal resolvins, given on day 3 after CFA injec tion, when heat hyperalgesia (reduction of paw withdrawal latency) is fully developed (Fig. 2a) , attenuated hyperalgesia in a dosedependent manner (Fig. 2b,c) . Notably, 10 ng of RvE1 produced an ~75% reduc tion in hyperalgesia 15 min after administration (Fig. 2b) . A meta analysis previously showed that dietary omega3 fatty acids alleviate inflammatory joint pain in patients 20 . The omega3 fatty acids eicos apentaenoic acid and docosahexaenoic acid, the respective precursors of RvE1 and RvD1, also reduced the severity of CFAevoked heat hyperalgesia (Fig. 2b) . But the effective doses of eicosapentaenoic acid and docosahexaenoic acid required were 10,000 times higher than that of RvE1 (Fig. 2b) . For direct comparison, 10 ng RvE1 was more potent than 10 µg of the COX2 inhibitor NS398 (Fig. 2c) . Notably, a stable analog, 19(pfluorophenoxy)RvE1 (19pfRvE1), designed to resist rapid local metabolic inactivation of RvE1 (ref. 21) , reduced hyperalgesia for 6 h (Fig. 2c) . By contrast, a further meta bolic product of RvE1, 18oxoRvE1 (ref. 21) , was essentially inac tive (Fig. 2c) . Although RvE1 potently reduced inflammatory pain, it did not alter baseline sensory thresholds in naive mice (Fig. 2d) . These findings suggest that resolvins have a unique role in the normalization of inflammatory pain.
We further investigated the peripheral role of resolvins in carrageenan elicited pain and inflammation. Intraplantar pretreatment with RvD1 and RvE1 substantially attenuated carrageenaninduced heat hyper algesia (Fig. 2e) . As expected, RvE1 had marked antiinflammatory effects, reducing carrageenaninduced edema, neutrophil infiltration and expression of proinflammatory cytokines (for example, TNFα, interleukin1β (IL1β) and IL6) and chemokines (for example, mono cyte chemotactic protein1 and macrophage inflammatory protein1α) in inflamed hindpaws ( Fig. 2f-h and Supplementary Fig. 4 ). Intra plantar RvE1 also rapidly attenuated formalininduced acute pain ( Supplementary Fig. 5a ).
To determine the potential mechanisms by which resolvins attenuate inflammatory pain, we examined the impact of RvE1 on TNFα signaling, because TNFα is a key contributor to the genesis of inflammation and pain via both peripheral 22, 23 and central 24 mechanisms. Indeed double knockout mice lacking both Tnfr1 and Tnfr2 (Tnfrsf1a −/− ;Tnfrsf 1b −/− ) showed a marked attenuation in CFAelicited heat hyperalgesia and formalinelicited secondphase pain (Fig. 3a) . Intrathecal injection of TNFα also evoked marked heat hyperalgesia, which was abrogated in mice lacking Trpv1, a crucial gene for generating heat hyperalgesia 25 . In contrast, formalininduced secondphase spontaneous pain was unaltered in Trpv1 −/− mice (Fig. 3b) . Spinal administration of RvE1 substantially reduced TNFα-induced heat hyperalgesia (Fig. 3c) . Hence, RvE1 can alleviate both TRPV1dependent and TRPVindependent inflammatory pain symptoms. To determine whether resolvins modulate spinal cord synaptic plas ticity, which is thought to underlie persistent inflammatory pain 10,11 , we used a patchclamp technique to record spontaneous excitatory postsynaptic currents (sEPSCs) in lamina II neurons ex vivo in isolated spinal cord slices from mice. Perfusion of spinal cord slices with TNFα induced an increase in the frequency but not amplitude of sEPSCs (Fig. 3d) , suggesting a presynaptic effect of TNFα achieved by increas ing glutamate release from axonal terminals 24 . Notably, RvE1 alone did not alter basal synaptic transmission but did block the TNFα-induced increase in sEPSC frequency (Fig. 3d) . The TRPV1 antagonist capsazepine also reduced this increase in sEPSC frequency by TNFα (Fig. 3d) , in parallel with earlier results that TNFα increased TRPV1 activity in DRG neurons 26, 27 . Direct activation of TRPV1 by capsaicin (100 nM) elicited a twofold increase in sEPSC frequency that was completely blocked by RvE1 (Fig. 3e) . Like RvE1, chemerin also abolished this fre quency increase by capsaicin in a pertussis toxin-dependent manner, suggesting the involvement of ChemR23 (Fig. 3e and Supplementary  Fig. 6 ). Notably, intrathecal capsaicin elicited acute spontaneous pain for <10 min, and intrathecal RvE1 prevented this induction of acute pain (Fig. 3f) . In parallel, peripheral RvE1 reduced intraplantar capsaicin induced acute pain (Supplementary Fig. 5b) . These results further establish that RvE1 attenuates inflammatory pain by blocking TRPV1 and TNFα signaling, presumably at presynaptic sites.
Next, we investigated whether resolvins modulate synaptic plas ticity via the ERK signaling pathway, because previous studies have reported that ChemR23 regulates ERK signaling in nonneuronal cells 18 , ERK activation in DRG neurons increases TRPV1 activity 28 and ERK modulates neurotransmitter release via phosphorylation of synapsin I 29 . We inhibited the ERK pathway with the mitogen activated protein kinase kinase (MEK) inhibitors U0126 and PD98059 and found that both blocked the capsaicininduced sEPSC increase, indicating a role for ERK in regulating presynaptic glutamate release in the spinal cord (Fig. 3e) . In dissociated DRG neurons, both TNFα and capsaicin elicited increases in phosphorylation of ERK (pERK), and RvE1 abolished these increases (Fig. 3g) . Thus, RvE1 might attenuate inflammatory pain by blocking ERKmediated glutamate release in presynaptic terminals in response to TNFα stimulation and TRPV1 activation (Fig. 3h) .
Apart from heat hyperalgesia, CFA and intrathecal TNFα produced another cardinal feature of inflammatory pain, mechanical allodynia (a reduction in paw withdrawal threshold). Intrathecal RvE1 also attenuated mechanical allodynia induced by TNFα or CFA (Fig. 4a and Supplementary Fig. 7a,b) . Of note, TNFα-induced mechanical allodynia was TRPV1 inde pendent (Fig. 4b) . To define potential mechanisms by which RvE1 attenuates mechanical allodynia, we examined the activa tion of glutamate NMDA receptors (NMDARs) in dorsal horn neurons, which results in hyperactivity of these neurons (cen tral sensitization) and, subsequently, mechanical allodynia 10, 19 . We measured the activity of NMDARs by recording NMDA induced currents in dorsal horn neurons. TNFα significantly potentiated NMDA currents, and RvE1 reduced this potentiation (Fig. 4c) . We further assessed whether RvE1 inhibits NMDAR acti vation via the ERK pathway, as ERK phosphorylation in dorsal horn neurons serves as a marker for central sensitization 13, 30 . Perfusion of spinal slices with TNFα induced robust ERK phosphorylation primarily in superficial dorsal horn neurons, and RvE1 treatment reduced the phosphorylation (Fig. 4d) . We found that ERK medi ates central sensitization via activation of NMDARs in postsynaptic dorsal horn neurons, because the MEK inhibitors PD98059 and U0126, but not capsazepine, blocked TNFα-induced NMDAR activation (Fig. 4e) . Thus, we postulate that RvE1 also attenuates inflammatory pain by inhibiting ERKmediated NMDAR activation in postsynaptic dorsal horn neurons (Fig. 4f) . In addition to dampening behavioral hypersensitivity in inflamma tory pain conditions, resolvins also reduced mechanical or heat hyper algesia in other persistent pain states, including incisioninduced postoperative pain (Supplementary Fig. 7c ) and nerve injuryinduced neuropathic pain (Supplementary Fig. 7d) .
In summary, these results show that resolvins, at very low doses (0.3-20 ng), effectively reduce inflammatory pain symptoms in several mouse models, through both peripheral and central actions. Biosynthesized during resolution of acute inflammation, resolvins are known to act on immune cells via antiinflammatory mechanisms (for example, reducing polymorphonuclear leukocyte infiltration and tissue injury) and proresolving actions (for example, increas ing phagocytic activity of macrophages) 2 . As expected, peripheral administration of RvE1 reduced carrageenanelicited expression of proinflammatory cytokines, neutrophil infiltration and paw edema. Because proinflammatory cytokines such as TNFα and IL1β are indispensable for the pathogenesis of inflammatory pain (Fig. 3a,b) 24, 31 , the antinociceptive effects of resolvins could be attribut able to its antiinflammatory role. Also, it is noteworthy that we show here a previously undescribed mechanism in pain resolution where RvE1 rapidly, within minutes, decreases inflammatory pain by modulating synaptic plasticity in dorsal horn neurons. RvE1 not only abolished TRPV1induced increases in EPSC frequency and spontaneous pain but also blocked TNFα-induced increases in EPSC frequency and NMDAR hyperactivity. Activation of the GPCR ChemR23 and inactivation of the ERK signaling pathway in both presynaptic and postsynaptic neurons are required for the antinociceptive effects of RvE1. Current treatments for inflammatory pain are limited by their side effects, for example, respiratory depression, sedation, nausea, vomiting, constipation, dependence, tolerance and addiction after opioid treatment 32, 33 and serious cardiovascular effects associated with longterm use of COX2 inhibitors 1, 34 . Additionally, COX2 inhibitors and local anesthetics impair the resolution of acute inflam mation 4, 6 . Although enthusiasm for the use of TRPV1 antagonists is high, these drugs can cause hyperthermia 35 and have limited effects on mechanical allodynia. Our results show that resolvins attenuate inflammatory pain without changing basal pain sensitivity. Given the antihyperalgesic efficacy of resolvins and the safety associated with endogenous mediators, resolvins and their metabolically stable analogs may represent a new family of analgesics useful in treating inflammationassociated pain states such as arthritic and post operative pain. This new analgesic function adds to the beneficial antiinflammatory and proresolving effects of resolvins 2 .
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